Trial Profile
A study evaluating safety and efficacy of direct-acting antiviral drug combinations in HIV/HCV coinfected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Daclatasvir/sofosbuvir (Primary) ; Dasabuvir (Primary) ; Dolutegravir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SCOLTA-HCV
- 08 Jul 2017 New trial record